NEW YORK (GenomeWeb News) – Molecular cytology firm Veracyte has filed for an initial public offering in the US.
The South San Francisco, Calif.-based firm was founded in 2006 as Calderome, but changed its name to Veracyte in early 2008.
NEW YORK (GenomeWeb News) – Veracyte announced today that Aetna will provide its members with coverage for the firm's Afirma Gene Expression Classifier, a genomic test used to clarify results as benign or suspicious for cancer.
NEW YORK (GenomeWeb News) – Veracyte and Genyzme today announced that the New York State Department of Health has cleared the way for Veracyte's molecular diagnostic test for inconclusive thyroid nodule results to be offered to patients in the state.
Results from a multi-center prospective validation study have confirmed the sensitivity and high negative predictive value of a gene expression test marketed by Veracyte to identify patients whose thyroid nodules are likely to be benign and who can thus avoid further diagnostic s